Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: A children's oncology group report

Pediatric Blood and Cancer

Volumn 62, Issue 1, 2015, Pages 60-64

  Trippett, Tanya M ^a   Schwartz, Cindy L ^b   Guillerman, R Paul ^c   Gamis, Alan S ^d   Gardner, Sharon ^e   Hogan, Shirley ^f   London, Wendy B ^g   Chen, Lu ^h   de Alarcon, Pedro ⁱ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

^d CHILDREN S MERCY HOSPITAL   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

ⁱ UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Hodgkin lymphoma; Ifosfamide; Re induction; Relapse; Vinorelbine

Indexed keywords

ELECTROLYTE; HEMOGLOBIN; IFOSFAMIDE; NAVELBINE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ABDOMINAL PAIN; ACIDOSIS; ADOLESCENT; ADULT; AGITATION; ALLERGY; ARTICLE; AUTOTRANSPLANTATION; CARDIOTOXICITY; CHILD; CHILDHOOD DISEASE; CONFUSION; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE URINE LEVEL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HALLUCINATION; HEART LEFT VENTRICLE FUNCTION; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFANT; INFECTION; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUROTOXICITY; NEUTROPENIA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; SECOND CANCER; SIDE EFFECT; SOMNOLENCE; STEM CELL TRANSPLANTATION; STOMATITIS; THERAPY DELAY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; DRUG RESISTANCE; MORTALITY; MULTIMODALITY CANCER THERAPY; NEWBORN; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PROGNOSIS; REMISSION; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; INFANT; INFANT, NEWBORN; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VINBLASTINE; YOUNG ADULT;

EID: 84922830869     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25205     Document Type: Article

References (26)

1. Longo D, Duffey P, Young R, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin disease after combination chemotherapy: the low probability of cure. J Clin Oncol 1992; 10:210-218.
2. Fisher R, Devita V, Hubbard S, et al. Prolonged disease-free survival in Hodgkin disease with MOPP re-induction after first relapse. Ann Intern Med 1979; 90:761-763.
3. Viviani S, Santoro A, Negretti E, et al. Salvage chemotherapy in Hodgkin disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1990; 1:123-127.
4. Yuen A, Rosenberg S, Hoppe R, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin disease. Blood 1997; 89:814-822.
5. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341:1051-1054.
6. Moskowitz C, Nimer S, Zelenetz A, et al. A two-step comprehensive high-dose chemotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2000; 97:616-623.
7. Rapoport A, Rowe J, Kouides P, et al. One hundred autotransplants for relapsed or refractory Hodgkin disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11:2351-2361.
8. Fields K, Elfenbein G, Perkins J, et al. Ifosfamide, carboplatin, and etoposide: A new regimen with a broad spectrum of activity. J Clin Oncol 1994; 12:544-552.
9. Pratt C, Luo X, Fang L, et al. Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: A single hospital experience. Med Pediatr Oncol 1996; 27:145-148.
10. Marina N, Rodman J, Shema S, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 1993; 11:554-560.
11. Cairo M. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. Semin Oncol 1995; 22:23-27.
12. Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: A pediatric oncology group phase I/II study. J Pediatr Hematol Oncol 1995; 17:265-269.
13. Kung FH, Harris MB, Krischer JP, et al. Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood. Med Pediatr Oncol 1999; 32:225-226.
14. Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study. Cancer 1993; 71:1898-1903.
15. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 2000; 95:1588-1593.
16. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: An active agent for the management of patients with heavily pretreated Hodgkin disease. Ann Oncol 1994; 5:817-820.
17. Bonfante V, Viviani S, Di Russo S, et al. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol Suppl 2001; 64:51-55.
18. Kuttesch JF, Krailo MD, Madden T, et al. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A children's oncology group study. Pediatr Blood Cancer 2009; 53:590-593.
19. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European organization for research and treatment of cancer, national cancer institute of the United States national cancer institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. part II: Analysis and examples. Br J Cancer 1977; 35:1-39.
22. Moskowitz CH, Yaholom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of the pre-transplant functional imaging. Br J Haematol 2010; 148:890-897.
23. Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation: CCG-591. J Clin Oncol 2001; 19:2390-2396.
24. Wimmer RS, Chauvenet AR, London WB, et al. APE chemotherapy for children with relapsed Hodgkin disease: A pediatric oncology group trial. Pediatr Blood Cancer 2006; 46:320-324.
25. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Hematologica 2007; 92:35-41.
26. Magagnoli M, Spina M, Balzarotti M, et al. IGEV regimen and a fixed dose of lenograstim: An effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant 2007; 40:1019-1025.